Stock Movers Hermes Drops, AstraZeneca Up, Brenntag Slumps
Jul 14, 2025
Hermes faces a decline as analysts downgrade its stock, citing challenges in the luxury market. In contrast, AstraZeneca's promising trial results for its new hypertension drug spark optimism, with potential blockbuster sales on the horizon. Meanwhile, Brenntag’s shares tumble after a profit warning, reflecting broader economic concerns. The podcast contrasts the struggles of luxury brands with the pharmaceutical sector's successes, highlighting a dynamic landscape in the stock market.
AI Snips
Chapters
Transcript
Episode notes
Tariffs Dampening Luxury Market
- Hermes and luxury goods face downward pressure mainly from tariffs and global economic concerns.
- Despite good Chinese data, tariffs overshadow growth prospects, limiting recovery in luxury valuations.
AstraZeneca's Promising Drug Trial
- AstraZeneca's hypertension drug Baxdrostat shows strong trial results meeting all required endpoints.
- This positions Baxdrostat as a potential blockbuster drug with sales possibly exceeding $5 billion annually.
Brenntag's Profit Warning Alert
- Brenntag cut full-year guidance due to industrial slowdown fears, particularly in Germany.
- Profit warning may signal broader challenges ahead for German chemical sector amid tariff concerns.